RATIONAL ANTIMICROBIAL THERAPY FOR THE TREATMENT OF EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the most urgent problems of modern health care because of the high prevalence and mortality. The frequency of COPD exacerbations is an extremely important factor influencing the choice of antimicrobial agent. In addition to the effects on the clinical symptoms of COPD exacerbations and mortality, antibiotics influence the length of time between exacerbations. Several studies have demonstrated the efficacy of a 5-day course of antibiotic therapy in COPD exacerbations.

Full Text

Restricted Access

About the authors

A. A Zaitsev

FSBEI HE «First MSMU n.a. I.M. Sechenov» of RMH

MD Moscow

References

  1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/
  2. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М., 2014. Доступно на: http://www.pulmonology.ru/publications/guide.php?clear_cache=Y
  3. Roche N., Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54(13): 1408-13.
  4. Fuhrman C., Delmas M. Epidemiology of chronic obstructive pulmonary disease in France. Rev. Mal. Respir. 2010; 27(2): 160-68.
  5. World Health Report 2000. Health systems: improving performance. Annex table 3. 2000 World Health Organization. Geneva, Switzerland.
  6. Center for Financing, Access and Cost Trends, Agency for Healthcare Research and Quality: Medical Expenditure Panel Survey, United States, 2012. Доступно на: http://www.ahrq.gov/
  7. Зайцев А.А. и др. Фармако-эпидемиологические аспекты антибактериальной терапии инфекционного обострения хронической обструктивной болезни легких в военном госпитале. Военно-медицинский журнал. 2007; 328(10): 63-4.
  8. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.
  9. Jorgensen A.F., Coolidge J., Pedersen P.A., Petersen K.P., Waldorff S., Widding E. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis: a doubleblind, placebo-controlled multicentre study in general practice. Scand. J. Prim. Health Care. 1992;10:7-11.
  10. Saint S., Bent S., Vittinghof E., Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analisis. JAMA. 1995; 273: 957-60.
  11. Ram F., Rodriguez-Roisin R., Granados-Navarrete A., Garcia-Aymerich J., Barnes N. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 3: 9.
  12. Puhan M., Vollenweider D., Latshang T., Steurer J., Steurer-Stev C. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 2007; 8: 30.
  13. Almirall J., Bolibar I., Toran P., Pera G., Boquet X., Balanzô X., Sauca G. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004; 125: 1335-42.
  14. Bafadhel M., Clark T., Reid C., Medina M.J., Batham S., Barer M.R., Nicholson K.G., Brigh-tling C.E. Procalcitonin and C-reactive protein in hospitalized adult patients with community acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011; 139(6): 1410-18.
  15. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Уральский мед. журн. 2008; 13: 19-24.
  16. Зайцев А.А., Овчинников Ю.В., Безлепко А.В. Клинические рекомендации по ведению больных с обострением хронической обструктивной болезни легких. Военно-медицинский журнал. 2015; 336(3): 31-7.
  17. ЗайцевА.А.,ОвчинниковЮ.В.,КондратьеваТ.В. Биологические маркеры воспаления при внебольничной пневмонии. Consilium Medicum. 2014; 16(11): 36-41.
  18. Christ-Crain M., Stolz D., Bingisser R., Müller C., MiedingerD., HuberPR.,ZimmerliW, HarbarthS., Tamm M., Müller B. Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia. Am. J. Respir. Crit. Care. Med. 2006; 174: 84-93.
  19. Long W., Deng X., Zhang Y., Lu G., Xie J., Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respir. 2011; 16(5): 819-24.
  20. Schuetz P., Suter-Widmer I., Chaudri A., et al. Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group. Prognostic value of procalcitonin in community-acquired pneumonia. Eur. Respir. J. 2011; 37(2): 384-92.
  21. Albrich W., Dusemund F., Bucher B., Meyer S., Thomann R., Kühn F., Bassetti S., Sprenger M., Bachli E., Sigrist T., Schwietert M., Amin D., Hausfater P., Carre E., Gaillat J.,Schuetz P., Regez K., Bossart R., Schild U., Mueller B., ProREAL Study Team. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in «real life»: an international, multicenter poststudy survey (ProREAL). Arch. Intern. Med. 2012; 172(9): 715-22.
  22. Li H., Luo Y.F., Blackwell T.S., Xie C.M. Meta-Analysis and Systematic Review of Procalcitonin-Guided Therapy in Respiratory Tract Infections. Antimicrob. Agents Chemother. 2011; 55(12): 5900-906.
  23. Sethi S., Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355.
  24. Diederen B., van der Valk P., Kluytmans J., Peeters M.F., Hendrix R. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 30: 240-44.
  25. Kherad O., Rutschmann O. Viral Infections as a Cause of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation. Praxis. 2010; 99(4): 235-40.
  26. Lode H., Allewelt M., Balk S., De Roux A., Mauch H., Niederman M., Schmidt-Ioanas M. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection. 2007; 35: 143-49.
  27. Синопальников А.И., Зайцев А.А. Антибактериальная терапия при обострении хронической обструктивной болезни легких: фокус на длительность «дезинфекционного» периода. Consilium Medicum. 2012; 14(3): 74-8.
  28. Siempos I., Dimopoulos G., Korbila I., Manta K., Falagas M. Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 2007. Доступно на: http://www.antibiotic.ru/print.php?sid=1538.
  29. Зайцев А.А. Обострение ХОБЛ. Практические рекомендации. Фарматека. 2014; 15: 51-7.
  30. Cazzola M., Vinciguerra A., Beghi G., et al. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J. Chemother. 1995; 7(5): 432-41.
  31. Цой А.Н., Сафонова Е.В., Гучев И.А. Цефиксим. Клиническая эффективность при обострении нетяжелой хронической обструк-тивной болезни легких и влияние на развитие рецидивов заболевания. Лечащий врач. 2011; 1. Доступно на http://www.lvrach.ru/2011/01/15435111/.
  32. Lorenz J., Steinfeld P., Drath L., Keienburg T., Troester K. Efficacy and Tolerability of 5-vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis. Clin. Drug Investig. 1998; 15(1): 13-20.
  33. Синопальников А.И., Зайцев А.А. Комплаентность пациентов с инфекциями дыхательных путей. Клиническая микробиология и антимикробная химиотерапия. 2008; 10(1): 50-9.
  34. Chodosh S., DeAbate C., Haverstock D., et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir. Med. 2000; 94: 18-27.
  35. Masterton R., Burley C. Randomized, doubleblind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents. 2001; 18: 503-12.
  36. Falagas M., Avgeri S., Matthaiou D., Dimopoulos G. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother. 2008; 62(3): 442-50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies